Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  irofulven
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-20 of 20 for your search:
Start Over
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000069317, MGI-IROF-003, UARIZ-HSC-00305, NCT00033735
Phase I/II Study of Irofulven in Patients With Progressive or Recurrent High-Grade Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, or Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-2005, JHOC-NABTT-2005, NCT00012038
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IROF-017, NCT00374660
Phase II Study of 6-Hydroxymethylacylfulvene for Advanced Renal Cell Carcinoma (Summary Last Modified 05/2000)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98009, MSKCC-98007, NCI-T97-0119, NCT00003390, T97-0119
Irofulven in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: DM97-308, P30CA016672, U01CA070172, MDA-DM-97308, NCI-T97-0113, CDR0000066469, T97-0113, NCT00003441
Phase II Study of 6-Hydroxymethylacylfulvene in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (Summary Last Modified 06/2000)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: VU-VCC-THO-9817, NCI-T97-0106, T97-0106
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000066696, NCI-98-C-0162, MB-403, NCI-T98-0030, T98-0030, NCT00019552
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066761, U10CA031946, CLB-39805, CALGB-39805, NCT00003666
Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066884, P30CA054174, UTHSC-9895011082, MGI-114.27.P98-03, SACI-IDD-98-18, NCI-V99-1517, NCT00003760
Phase II Study of 6-Hydroxymethylacylfulvine (MGI-114) in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 04/2000)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-DM-98221, NCI-T98-0071, T98-0071
Irofulven in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: CDR0000066939, UTHSC-IDD-98-23, SACI-IDD-98-23, NCI-T98-0060, T98-0060, NCT00003796
Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067554, GOG-129L, NCT00005031
Irofulven in Treating Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 99-0468.cc, UCHSC-99468, NCI-T99-0070, T99-0070, NCT00005968
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 85
Sponsor: NCI
Protocol IDs: NCI-2012-02512, CDR0000269484, GOG-0146O, U10CA027469, NCT00053365
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IROF-019, NCT00124527
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IROF-018, NCT00124566
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-01838, POG-9772, CDR0000066359, P9772, NCT00003370
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02309, MDA-ID-99060, NCI-T99-0043, CDR0000067207, T99-0043, NCT00003997
Start Over